Ho-Sheng Lin

Title: Ho-Sheng Lin: Innovator in Cancer Detection Technology

Introduction

Ho-Sheng Lin is a prominent inventor based in Plymouth, MI (US). He has made significant contributions to the field of cancer diagnostics, particularly in the detection of head and neck squamous cell carcinoma (HNSCC). His innovative work has the potential to improve patient outcomes through early detection and personalized treatment strategies.

Latest Patents

Ho-Sheng Lin holds a patent for "Neoepitope detection of disease using protein arrays." This diagnostic device and method are designed to detect the presence of HNSCC in patients. The device includes a panel of markers indicative of HNSCC, allowing for accurate diagnosis and staging of the disease. Additionally, his patent outlines methods for personalized immunotherapy, the creation of personalized anti-cancer vaccines, and predicting clinical outcomes in HNSCC patients. This patent represents a significant advancement in cancer diagnostics and treatment.

Career Highlights

Ho-Sheng Lin is affiliated with Wayne State University, where he continues to engage in groundbreaking research. His work focuses on developing innovative diagnostic tools that can lead to better management of cancer patients. With a patent portfolio that includes 1 patent, Lin is recognized for his contributions to medical technology.

Collaborations

Throughout his career, Ho-Sheng Lin has collaborated with notable colleagues, including Michael A. Tainsky and Sorin Draghici. These partnerships have fostered a collaborative environment that enhances research and innovation in cancer detection.

Conclusion

Ho-Sheng Lin's work in the field of cancer diagnostics exemplifies the impact of innovation on healthcare. His patented technologies have the potential to revolutionize the way HNSCC is detected and treated, ultimately improving patient care and outcomes.